Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6287590 | 0.92 | TLR7 (0.46) | TLR7CA12CA1CA2CA9 | |
| SCHEMBL6095597 | 0.91 | TLR7 (0.50) | TLR7PIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL6777327 | 0.90 | TLR7 (0.34) | TLR7CA12CA1CA2CA9 | |
| SCHEMBL4793822 | 0.88 | TLR7 (0.37) | TLR7 | |
| SCHEMBL6783236 | 0.86 | GRIA1 (0.33) | TLR7CA12CA1CA2CA9 | |
| SCHEMBL6779020 | 0.84 | TLR7 (0.33) | TLR7PIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL6780037 | 0.84 | CYP3A4 (0.40) | TLR7CA12CA1CA2CA9 | |
| SCHEMBL6773797 | 0.82 | KMT2A (0.43) | TLR7PTGES | |
| SCHEMBL6778418 | 0.82 | TLR7 (0.39) | TLR7CA12CA1CA2CA9 | |
| SCHEMBL5030248 | 0.81 | TLR7 (0.44) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312434-A1 | PROCESS FOR IMIDAZO [4,5-C] PYRIDIN-4-AMINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080312434-A1 | PROCESS FOR IMIDAZO [4,5-C] PYRIDIN-4-AMINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080312434-A1 | PROCESS FOR IMIDAZO [4,5-C] PYRIDIN-4-AMINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-20050032829-A1 | Process for imidazo[4,5-c]pyridin-4-amines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312434-A1 | PROCESS FOR IMIDAZO [4,5-C] PYRIDIN-4-AMINES | PAICS, HTR4, PNPO | TLR7 974/4885HTT 2068/4885CA12 4689/4885 |
| US-20050032829-A1 | Process for imidazo[4,5-c]pyridin-4-amines | PAICS, HTR4, PNPO | TLR7 974/4885HTT 2068/4885CA12 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.